Susvimo is the only continuous delivery treatment to provide reliable, long-term vision outcomes in nAMD, the leading cause ...

Roche’s Genentech has reported new five-year data from the Phase III Portal trial, confirming the safety, durability, and ...

Genentech's Portal study shows Susvimo maintains vision and retinal drying in wet AMD patients over five years with biannual ...

Basel: Roche has announced new, five-year efficacy, safety and durability data from the Phase III Portal study, a long-term ...

Swiss pharma giant Roche announced positive five-year efficacy, safety and durability data from the Phase III Portal study, a ...

Roche’s Susvimo maintains vision over five years with two refills per year in people with neovascular age-related macular degeneration: Basel Monday, August 4, 2025, 11:00 Hrs [ ...

The development of drug delivery platforms that offer sustained release of therapeutic agents in the retina represents a vital evolution in ophthalmic practice.While the ongoing emergence of effective ...

Anti-VEGF and anti-complement therapies work on distinct mechanisms in age-related macular degeneration, and both may be ...

Ixo-vec reduced anti-VEGF injection frequency and was well tolerated in patients with wet AMD. A phase 3 pivotal trial ...

US approval for Susvimo for diabetic retinopathy, a potentially blinding eye disease EU approval for Itovebi for a type of advanced breast cancer and Evrysdi tablet for spinal muscular atrophy ...

Detailed price information for Roche Holdings Ltd ADR (RHHBY) from The Globe and Mail including charting and trades.

The companion product – Susvimo – is an implantable treatment based on ranibizumab that can extend the time between treatments to six months or more and was approved by the FDA last October.